Unknown OBSERVATIONAL NCT02627703

(Oncotype DX®) in Estrogen Receptor Positive (ER+) HER-2 Negative (HER 2-) 1-3 Node Positive (pN1) Breast Cancer

A Prospective Clinical Utility Study of the Impact of the 21 Gene Recurrence Score® Assay (Oncotype DX®) in Estrogen Receptor Positive (ER+) HER-2 Negative (HER 2-) 1-3 Node Positive (pN1) Breast Cancer in Multiple BC Cancer Agency Centres

Sponsor: British Columbia Cancer Agency

Conditions Breast Cancer

Interventions Oncotype DX

Updated 7 times since 2017 Last updated: Jul 18, 2016 Started: May 31, 2010 Primary completion: Dec 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Breast Cancer and is currently ongoing. British Columbia Cancer Agency leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status
Aug 2018 — Jan 2021 [monthly]

Unknown Status

Status: Recruiting → Unknown Status
Jun 2018 — Aug 2018 [monthly]

Recruiting

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Recruiting

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Recruiting NA

First recorded

May 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

British Columbia Cancer Agency
Genomic Health®, Inc.

Data source: British Columbia Cancer Agency

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vancouver, Canada